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Members of the Burkholderia cepacia complex (Bcc) cause chronic opportunistic lung infections in people with cystic fibrosis
(CF), resulting in a gradual lung function decline and, ultimately, patient death. The Bcc is a complex of 20 species and is rarely
eradicated once a patient is colonized; therefore, vaccinationmay represent a better therapeutic option.We developed a new
proteomics approach to identify bacterial proteins that are involved in the attachment of Bcc bacteria to lung epithelial cells.
Fourteen proteins were reproducibly identified by two-dimensional gel electrophoresis from four Bcc strains representative of
two Bcc species: Burkholderia cenocepacia, the most virulent, and B. multivorans, the most frequently acquired. Seven proteins
were identified in both species, but only two were common to all four strains, linocin and OmpW. Both proteins were selected
based on previously reported data on these proteins in other species. Escherichia coli strains expressing recombinant linocin and
OmpW showed enhanced attachment (4.2- and 3.9-fold) to lung cells compared to the control, confirming that both proteins are
involved in host cell attachment. Immunoproteomic analysis using serum from Bcc-colonized CF patients confirmed that both
proteins elicit potent humoral responses in vivo. Mice immunized with either recombinant linocin or OmpWwere protected
from B. cenocepacia and B. multivorans challenge. Both antigens induced potent antigen-specific antibody responses and stimu-
lated strong cytokine responses. In conclusion, our approach identified adhesins that induced excellent protection against two
Bcc species and are promising vaccine candidates for a multisubunit vaccine. Furthermore, this study highlights the potential of
our proteomics approach to identify potent antigens against other difficult pathogens.
Vaccination is the most effective medical intervention intro-duced. In the context of the global rise in antimicrobial resis-
tance, vaccines are essential weapons in the fight against bacterial
infections. Vaccines do not posemassive selection pressure on the
environment, nor do they contribute to antimicrobial resistance
(1). However, identification of good vaccine antigens remains
challenging. To date, several strategies that identify effective vac-
cine antigens have been described, including the reverse-vaccin-
ology approach (2). Rappuoli and colleagues pioneered the use of
reverse vaccinology to identify novel antigens against Neisseria
meningitidis serogroup B. They sequenced the genome, identified
350 surface proteins, and administered these proteins to mice to
identify those proteins that were immunogenic (3). This predic-
tive approach assumes that proteins that are able to induce pro-
tective immunity are located outside the cellmembrane and there-
fore possess signal sequences (4). Immunoproteomics has also
been used to identify novel antigens that elicit an immune re-
sponse, as recently reviewed (5), but when used in isolation, it has
limitations, and no efficacious antigens have yet been identified by
using this approach. Indeed, the confirmed prophylactic Borde-
tella pertussis antigen filamentous hemagglutinin (FHA), a com-
ponent of most licensed acellular whooping cough vaccines, was
undetectable in two immunoproteomic studies (6, 7).
We have developed a novel proteomic-based strategy to iden-
tify bacterial adhesins that are involved in host cell attachment and
demonstrated that two of these adhesins were protective against
the Burkholderia cepacia complex (Bcc). This bacterial pathogen
complex comprises a group of 20 species of Gram-negative bacte-
ria (8–11), 2 of which, Burkholderia multivorans and B. cenocepa-
cia, are the most clinically relevant (12, 13). Members of the Bcc
are reported to cause infections in up to 5% of cystic fibrosis (CF)
patients in theworld, which is significant, as CF patients colonized
with Bcc experience a more rapid decline than do those colonized
with themore commonly acquired pathogenPseudomonas aerugi-
nosa (14, 15). Once a patient is colonized with Bcc bacteria, these
bacteria are rarely eradicated due to the resistance of the Bcc to
antibiotics (16) and antimicrobial peptides (17, 18). Strict segre-
gation measures have limited the patient-to-patient spread of the
most virulent species, B. cenocepacia (19). Currently, the majority
of new acquisitions are from the environment, withB.multivorans
being the most frequently acquired (20); therefore, the Bcc still
represents a substantial threat to CF patients. B. cenocepacia is
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subdivided into four clusters by phylogenetic analysis of the recA
gene sequence (subgroups IIIA, IIIB, IIIC, and IIID) (21). While
all four groups include clinical isolates, subgroup IIIA is associated
with more epidemic strains, which have a higher mortality rate
than that associated with other B. cenocepacia groups (22). More-
over, Bcc contamination of pharmaceutical formulations,medical
devices, and disinfectants has led to a number of outbreaks among
both CF and non-CF populations (22). Bcc is also an emerging
pathogen in nosocomial infections among chemotherapy patients
and other immunosuppressed individuals (23, 24). The high level
of antibiotic resistance combined with the continued acquisition
of Bcc bacteria from the environment suggests that prevention of
infection with a prophylactic vaccine may be a better approach
than eradication of existing infections. Only two in vivo mouse
vaccination studies have reported protection against the Bcc, both
of which involved unpurified outer membrane protein (OMP)
preparations (25, 26).No vaccine antigens have been identified for
the Bcc to date.
The majority of mucosal pathogens colonize by attaching to
host cells and/or host proteins. Previous work in our laboratory
has shown that Bcc attaches laterally to the surfaces of epithelial
cells, prior to invasion inside the cells (27). Proteins that are in-
volved in bacterial attachment to host cells were previously proven
to be excellent vaccine antigens. A classic example is Bordetella
pertussis FHA,which is involved in attachment to epithelial cells of
the airways (28). FHA has been combined with other proteins
with adhesin properties (pertactin, pertussis toxin, and fimbriae 2
and 3) in approved prophylactic vaccines against whooping cough
(29).
Little is known about how Bcc attaches to lung epithelial cells.
A 22-kDa cable pilus protein was identified as an adhesin; how-
ever, it is expressed in only a subset of B. cenocepacia strains, i.e.,
piliated strains of the subgroup IIIA lineage only (30), and is not
expressed in the more frequently acquired species B. multivorans.
More recently, Mil-Homens et al. identified two closely related
trimeric autotransporters that are involved in B. cenocepacia ad-
hesion to lung epithelial cells (31, 32). We have developed a pro-
teomics approach to identify other bacterial proteins that are in-
volved in the attachment of Bcc to lung epithelial cells in vitro by
probing two-dimensional (2D) blots of bacterial proteins with
epithelial cells. Several of the identified proteins were subse-
quently found to be immunoreactive by using sera from Bcc-col-
onized CF patients. Two of these proteins protected immunized
mice from Bcc infection. This approach should also allow the
identification of a wide range of adhesins in other bacteria and
consequently enable the development of potent vaccine antigens
for a range of mucosal pathogens against which there are no pro-
tective vaccines to date.
MATERIALS AND METHODS
Ethics statement. Animal immunizations were performed in compliance
with animal protection legislation (Directive 2010/63/EUof the European
Parliament and of the Council of 22 September 2010 on the protection of
animals used for scientific purposes) (65). Authorization for immuniza-
tions was obtained from the Irish Department of Health and the Health
Products Regulation Authority (HRPRA). Animals were maintained and
all studies were performed in accordance with regulations of the Irish
Department of Health and the HPRA and with the approval of the May-
nooth University Ethics Committee. Patient consent was obtained for the
use of serum, and ethics approval was obtained from the St. Vincent’s
University Hospital (SVUH) Ethics and Medical Research Committee
and from the ITT Dublin Research and Ethics Committee for the use of
stored serum.
Bacterial strains and culture conditions.To enhance coverage across
the two most clinically relevant species, two strains of each species were
analyzed, including piliated and nonpiliated B. cenocepacia strains (BC7
and C1394, respectively). The four bacterial strains used, the two B. mul-
tivorans strains LMG13010 and C1962 and the two B. cenocepacia strains
BC7 (recA IIIA lineage) and C1394 (recA IIIB lineage), are detailed in
Table 1 and were obtained from the BCCM/LMG, University of Ghent,
Ghent, Belgium, and routinely plated onto B. cepacia-specific agar
(BCSA) (33). All bacterial strains were routinely grown in Luria-Bertani
(LB) broth at 37°C with orbital shaking (150 rpm). To isolate sufficient
quantities of membrane proteins, bacterial cultures were grown in a 10-
liter fermentor. Five hundred milliliters of bacterial cultures grown over-
night in a 37°C incubator on a shaker at 150 rpm was inoculated into 10
liters of LBmedium. The culture was grown at 37°C at 150 rpmwithout a
pH control or antifoam control, with an air supply of 6 liters/min. Bacte-
rial cultures in stationary phase (optical density [OD] of 1.0)were used for
OMP extraction. All spent media and the cell pellet were autoclaved after
protein extraction.
Cell culture. 16HBE14o and CFBE41o lung epithelial cells were
generous gifts from Dieter Gruenert (UCSF). The human bronchial epi-
thelial cell line 16HBE14o was routinely grown in Eagle’s minimal es-
sential medium (EMEM)with 10% fetal bovine serum (FBS), 1% penicil-
lin-streptomycin, 1% L-glutamine, and 1% sodium pyruvate and
incubated in a 5% CO2 environment at 37°C (34). CFBE41o
 cells were
routinely grown inminimal essential mediumwith 10% FBS, 1% penicil-
lin-streptomycin, 1% L-glutamine, 1% sodium pyruvate, and 1% nones-
sential amino acids and incubated in a 5% CO2 environment at 37°C.
Attachment of Bcc to epithelial cells. In order to quantitate the at-
tachment of Bcc strains to lung epithelial cells, 16HBE14o or CFBE41o
cells were seeded into coated chamber slides (4 105 cells/chamber) for
24 h prior to incubation individually with B. cenocepacia strain BC7 or
C1394 or B. multivorans strain LMG13010 or C1962 for 30 min at a mul-
tiplicity of infection (MOI) of 50:1 or 10:1. Cells were gently washed three
times with phosphate-buffered saline (PBS) for 5min each and fixed with
3% (vol/vol) paraformaldehyde for 10 min at room temperature (RT).
The cells were then incubated with 5% (wt/vol) bovine serum albumin
(BSA) in PBS at room temperature for 1 h to block nonspecific binding.
After blocking, the samples were incubated with primary rabbit poly-
clonal anti-Bcc antibody (1:1,000 dilution) overnight at 4°C (R418, a gen-
erous gift from Uma Sajjan) (35), and bound antibodies were detected
with a fluorescein isothiocyanate (FITC)-labeled secondary antibody (1:
100) for 1 h at room temperature in the dark. Cells were counterstained
with 4=,6-diamidino-2-phenylindole (DAPI) for 15 min at room temper-
ature in the dark and visualized under fluorescence and confocal micro-
scopes to count the bacteria attached to the cells.
Preparation of bacterial membrane proteins. Stationary-phase (OD
of 1.0) cultures were collected by centrifugation for membrane protein
extraction as previously described (36). Briefly, after centrifugation at
5,000 g for 10 min at 4°C, the cell pellets were resuspended in ice-cold
TABLE 1 Strains used in this study and their sources
Species and
strain
BCCM/LMG
collection
designation Description Reference(s)
B. multivorans
LMG13010T LMG13010T CF patient, Belgium 62
C1962 LMG16665 Abscess, UK 62
B. cenocepacia 21, 62
BC7 LMG18826 CF, recA IIIA, piliated, Canada 21, 62
C1394 LMG16659 CF, recA IIIB, nonpiliated, UK 21, 62
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PBS containing 5% (vol/vol) 3-[(3-cholamidopropyl)dimethylammo-
nio]-1-propanesulfonate (CHAPS) with a protease inhibitor cocktail
(Roche, Penzburg, Germany). Bacterial membranes were collected and
washed in a series of five ultracentrifugation steps, and membrane pellets
were finally resuspended in 50 mM Tris (pH 8) buffer with a protease
inhibitor cocktail. The protein concentration was determined by a bicin-
choninic acid assay and Bradford assays (37).
Cell attachment blots. The membrane proteins were solubilized for
isoelectric focusing (IEF) in a rehydration solution containing 8Murea, 2
M thiourea, 4% CHAPS, 1% (vol/vol) Triton, 10 mM Tris base, 65 mM
dithiothreitol (DTT), and 0.8% (vol/vol) immobilized pH gradient (IPG)
buffer (pH3-11NL) (GE Life Sciences), and duplicate samples were sepa-
rated on simultaneously run gels by two-dimensional electrophoresis as
described previously (36). For each experiment, one gel was stained with
Coomassie blue (PageBlue; Fermentas), while the other was transferred
onto a polyvinylidene difluoride (PVDF)membrane after equilibration in
transfer buffer (25mM [wt/vol] Tris, 192mM [wt/vol] glycine, 20% [vol/
vol] methanol) (38) for 15 min. Protein transfer to an Immobilon-P
membrane was carried out in a Transphor unit (Bio-Rad) at 330 mA for
50min, and the membrane was blocked overnight with 5% BSA in PBS at
4°C on a shaker at 10 rpm. Lung epithelial cells (either CFBE41o or
16HBE14o) were scraped from flasks, washed with PBS, and incubated
with the blots for 4 h at 37°C on a shaker at 60 rpm. The blots were rinsed
with 20 ml of PBS, and the bound epithelial cells were fixed with 3%
paraformaldehyde dissolved in PBS. The cells were detected with an anti-
epithelial cell-specific antigen antibody (Millipore) by incubating the
blots with the mouse anti-epithelial cell antibody (1:1,000 in 5% [wt/vol]
BSA plus 0.04% [wt/vol] Tween 20 in PBS [PBS-T]) overnight at 4°C on a
shaker at 10 rpm. The blots were washed three times and incubated with
horseradish peroxidase (HRP)-conjugated anti-mouse antibody (1:
40,000 in 5% [wt/vol] BSA plus 0.04% [wt/vol] PBS-T) at room temper-
ature. Each blot was then washed five times, and chemiluminescence de-
tection was carried out by using the Santa Cruz luminol detection kit.
Each experiment was repeated at least twice with independent bacterial
membrane preparations. An overview of this method is shown in Fig. 1.
MALDI-TOFMS/MSanalysis.Thedeveloped chemiluminescent film
was carefully overlaid onto the corresponding Coomassie blue-stained
gel. Protein spots that corresponded to positive spots on the film were
excised from stained gels and destained with an equal volume of 100 mM
ammonium bicarbonate and acetonitrile. Gel digestion was performed
with 13 ng/l of modified porcine trypsin for 2 h on ice, followed by
overnight incubation at 37°C. Tubes were cooled to room temperature,
and gel pieces were pelleted. Aliquots of 2 to 2.5l of the supernatant were
withdrawn directly from the digest for matrix-assisted laser desorption
ionization–time of flight (MALDI-TOF) tandemmass spectrometry (MS/
MS) analysis, without further extraction of the gel pieces (39). MALDI-
TOFMS/MS analysis was performed by using a Bruker UltraflexMALDI-
TOF instrument (Bruker Daltonics, Bremen, Germany) with a ground
steel target plate as previously described (36).
Immunoblot analysis of membrane proteins from Bcc with CF pa-
tient sera. Two-dimensional blots were prepared from Bcc membrane
protein extracts as described above. The blots were blocked with 5% BSA,
2% Marvel dried milk powder overnight at 4°C before probing with
pooled serum from seven CF patients who had been positively identified
as having a Bcc infection or with sera from six CF patients who had no
history of Bcc infection, which were used as negative controls (1:80,000),
as previously described (36). The blots were then washed with PBS con-
taining 0.05% Tween 20, before incubation with HRP-conjugated anti-
human antibody (1:16,000; Roche), and washed again, and the immuno-
reactive proteins were detected by chemiluminescence as previously
described (36). The data for linocin and OmpW are presented, highlight-
ing the strains in which these two proteins were identified, together with
the sequence coverage and Mascot scores obtained.
Cloning and expression of membrane protein. The presence of each
gene in the four strainswas confirmedby isolating bacterial genomicDNA
using the DNeasy blood and tissue kit (Qiagen, Manchester, England).
FIG 1 Schematic of the workflow used to identify Bcc adhesins from bacterial membrane proteins. Themembrane proteins were analyzed by using 2D gels, and
pairs of gels were either blotted onto PVDF membranes or stained with Coomassie blue. The blots were probed with lung epithelial cells, followed by detection
of bound cells by antibodies. Positive spots on exposed chemiluminescent films were matched to the paired Coomassie blue-stained gels, and the proteins in the
corresponding gel-based spots were excised, trypsin digested, and identified by MALDI-TOF MS analysis.
McClean et al.
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Specific primers were designed according to linocin and OmpW se-
quences of the sequenced B. multivorans strain, ATCC 17616, from the
NCBI. PCR amplification was carried out with a Hot Start high-fidelity
PCR kit (Qiagen) using the following thermal cycle program: initial acti-
vation for 5 min at 95°C followed by 35 cycles consisting of denaturation
at 94°C for 30 s, annealing at 50 to 68°C for 30 s, and extension at 72°C for
30 s. For the last cycle, the incubation period at 72°C was extended to 5
min and samples were then maintained at 4°C.
Both geneswere cloned fromB.multivoransLMG13010, as this species
is currently the more commonly acquired species of the Bcc. Primers to
amplify the genes were designed from the B. multivorans ATCC 17616
sequence, with CACC at the 5= end to facilitate directional cloning. The
forward and reverse primers used were 5=-CACCATGAACAATCTGCAC
CGCGAACTC and 5=-ATCAGGCGGGCGTGCCGGC for linocin and
5=-CACCATGCATAAACCAATGACA and 5=-CTAGAACTTCATCCCG
ACACC for OmpW (CACC sites are underlined). Following amplifica-
tion of the genes by using AccuPrime TaqDNA polymerase, the products
were confirmed by agarose gel electrophoresis and cloned into the pET
100 vector. Escherichia coli transformations were carried out with One
Shot TOP10 competent cells by heat shock according to the manufactur-
er’s protocol. Transformed cultures were then spread onto LB agar plates
with ampicillin (100 g/ml) and incubated overnight at 37°C, and the
presence of the insert was confirmed by restriction digestion and agarose
gel electrophoresis. BL21 Star(DE3) One Shot E. coli cells (Life Technol-
ogies) were used as the host for expression. Once expression was con-
firmed in a pilot study using anti-His tag detection inWestern blots from
5-ml cultures, larger cultures of BL21 cells (1 liter to 1.5 liters) containing
the plasmid of interest were grown in LB medium with ampicillin (100
g/ml) and induced with 1 mM isopropyl--D-thiogalactopyranoside
(IPTG). The cultures were then centrifuged at 5,000 rpm for 10 min, and
the pellets were frozen at80°C until purification was performed.
Purification of His-tagged recombinant protein. The expressed bac-
terial proteins were extracted from bacterial pellets with the B-PER bac-
terial protein extraction reagent (Thermo Scientific) with an EDTA-free
protease inhibitor cocktail (Roche) and incubated for 15 min at room
temperature. The lysates were centrifuged at 15,000  g for 5 min to
separate soluble proteins from insoluble proteins. HisPur Ni-nitrilotri-
acetic acid (NTA) spin columns (Thermo Scientific) were used to purify
polyhistidine-tagged proteins from the protein extract. The samples were
mixed with an equal volume of equilibration buffer and spun down in the
Ni-NTA column. The columns were washed three times with wash buffer
containing 25mM imidazole. After washing the column, the sampleswere
then eluted with 250 mM imidazole, and the fractions were analyzed by
SDS-PAGE. The purified recombinant proteins were desalted with a Zeba
spin desalting column (Thermo Scientific, Dublin, Ireland). Detoxi gel
endotoxin removal columns (Thermo Scientific) were used to remove the
endotoxins from the recombinant proteins. The columns were regener-
ated with 1% sodiumdeoxycholate andwashed with nonpyrogenic water.
The protein samples were applied onto the column, and the flowthrough
was collected and kept at80°C. A ToxinSensor Gel Clot endotoxin assay
kit (GenScript, Piscataway, NJ) was used to determine the endotoxin lev-
els in the purified proteins. In each case, the endotoxin levels were0.25
endotoxin units (EU)/ml.
Immunization of recombinant proteins. All procedures involving
animals were carried out by licensed personnel according to approved
guidelines. Pathogen-free BALB/c mice (females 6 to 8 weeks old) were
housed in groups of five under standard pathogen-free conditions, with
food and water available. Mice (n  5 per group) were vaccinated with
two administrations of either antigen, 4 weeks apart. Intraperitoneal (i.p.)
immunizations were performed with 50 g of recombinant protein per
mouse and an equal volume of Imject alum (Thermo Scientific Pierce,
Rockford, IL). Bacterial challenge studies were performed 2 weeks follow-
ing booster vaccination, with immunosuppression by i.p. injection of 50
g of cyclophosphamide on days1 and 4 of challenge (25). The immu-
nized and nonimmunized mice were challenged with 4  107 B. cenoce-
pacia BC7 or B. multivorans LMG13010 bacteria suspended in 20 l of
PBS instilled intranasally, and mice were maintained for 5 days before
sacrifice by cervical dislocation. The lungs, spleen, and blood were col-
lected under aseptic conditions, and each organwas placed into individual
containers containing 1 ml of Ringer’s solution. Blood was kept at RT for
4 h to clot and then centrifuged at 1,600  g for 15 min to collect the
serum. Aliquots of serum were then kept at 80°C for further analysis.
The lungs and spleen were homogenized, serially diluted in Ringer’s so-
lution, and plated onto BCSA plates. All plates were then incubated for 72
h at 37°C prior to manual CFU enumeration.
Determination of antigen-specific antibodies by an ELISA.An indi-
rect enzyme-linked immunosorbent assay (ELISA) was used to evaluate
the specific immunogenic effects of linocin and OmpW. Ninety-six-well
Nunc-Immuno MaxiSorp assay plates were coated with 2 g/well of pu-
rified antigen, either linocin or OmpW, in coating buffer (sodium bicar-
bonate, pH 9.4). After overnight incubation at 4°C, the plates were
blocked with 10% BSA in PBS for 1 h at RT. Serial 4-fold dilutions of
serum in 1%BSAwere added (100l/well), and the plates were incubated
for 2 h at room temperature. After four washes with PBS–0.05% Tween
20, horseradish peroxidase-conjugated goat anti-mouse IgG1, IgG2a, or
IgG2b antibody (Abcam, Cambridge, United Kingdom) was added at a
1:5,000 dilution in 1% BSA. Following 2 h of incubation at RT, the plates
were washed four times before tetramethylbenzidine substrate (Pierce,
Thermo Scientific, Rockford, IL, USA) was added. Reactions were
stopped after 20minwith 2NH2SO4, and the absorbancewas determined
at awavelength of 450 nm. Serumantibody titerswere defined as endpoint
titers, i.e., the reciprocal of the highest dilution of serumproducing anOD
above the cutoff value, where the cutoff values were determined as theOD
of the corresponding dilution of control sera plus 3 standard deviations.
Visualization of recombinant bacterial cell attachment to lung cells.
CFBE41o cells were seeded into chamber slides (Lab-Tek; Thermo Sci-
entific) 24 h prior to experiments. E. coli BL21 control and E. coli BL21
recombinant protein-expressing strains at an OD at 600 nm (OD600) of
0.6 were treated by the addition of IPTG (1mM) to all three cultures for 3
h to induce recombinant protein expression. An aliquot of 500 l was
removed to confirm protein expression by SDS-PAGE analysis. Bacteria
were applied to CFBE41o cells at an MOI of 50:1, and the cells were
incubated for 30 min at 37°C in 5% CO2 to allow the bacteria to attach.
Cells and bacteria were gently washed four times with PBS (500 l) and
then fixedwith 3%paraformaldehyde for 10min at RT. Cells werewashed
with PBS and blocked with PBS containing 5% BSA for 1 h at RT before
incubation overnight at 4°C with FITC-conjugated anti-E. coli antibody
(1:100 dilution in 5% BSA in PBS). The following day, cells were washed
three times in PBS before staining with phalloidin-Alexa Fluor 568 (5
U/ml) and DAPI (1 g/ml) for 1 h in the dark. Samples were then
mounted with a drop of Vectashield mounting medium (Vector Labora-
tories, Peterborough, England) containing DAPI and visualized under a
confocal microscope. The cells were counted in 20 randomly selected
fields for each strain, and values are expressed as numbers of bacteria per
100 cells.
Cell-mediated immune responses following immunization.Groups
of 5 mice were immunized with linocin or OmpW as outlined above but
not treated with cyclophosphamide or challenged. Two weeks after
booster immunization, the animals were sacrificed, and spleens from
these animals were removed into RPMI 160 medium. Spleen cells from
immunized and nonimmunized mice were disrupted, and red blood cells
were lysed by using red blood cell lysis buffer (BioLegend, SanDiego, CA).
Cells were plated at 2 105 cells per well into 96-well plates in triplicate
and exposed to PBS alone, linocin (50 g/ml), or OmpW (50 g/ml).
Cells were incubated for 3 days before removal of the supernatant, and the
levels of the cytokines gamma interferon (IFN-), interleukin-4 (IL-4),
IL-6, IL-10, and IL-17Aweremeasured by using amouse cytometric bead
array (BectonDickinson,UnitedKingdom) according to themanufactur-
er’s instructions. Flow cytometry standard (FCS) data files were analyzed
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by FCAPArray software to generate standard curves and to determine the
cytokine concentrations for unknown samples.
Statistical analysis. Attachment of Bcc strains and E. coli strains ex-
pressing recombinant linocin or OmpW to lung epithelial cells was ana-
lyzed by one-way analysis of variance (ANOVA).Data relating to bacterial
CFU in lung and spleen following challenge were analyzed by two-way
ANOVA. Data relating to cytokine secretion from splenocytes were ana-
lyzed by Student’s t tests.
RESULTS
Attachment of Bcc strains to lung epithelial cells. In order to
compare the binding of the bacterial strains to host cells with and
without a CF phenotype, fluorescence microscopy was used to
quantify the attachment of the two B. multivorans and the two B.
cenocepacia strains to lung epithelial cells with (CFBE41o) and
without (16HBE14o) a CF phenotype. It was evident that all four
Bcc strains showed	2-fold more attachment to CFBE41o cells
than to the independently derived cell line 16HBE14o (P 
0.002) (Fig. 2) at an MOI of 50:1. This 2-fold (or greater) differ-
ence was also noted at an MOI of 10:1 for all strains (P  0.005)
except B. cenocepacia C1394 (Fig. 2A). B. multivorans strain
LMG13010 showed 4.4- and 6.5-fold more attachment to
CFBE41o cells than to 16HBE14o cells at MOIs of 10:1 and
50:1, respectively (Fig. 2A and B). The binding of the nonpiliated
B. cenocepacia strain C1394 was not significantly different from
that of the piliated B. cenocepacia strain BC7 for either cell line
(P 0.128). It was also apparent that, overall, no differences were
observed in the attachment of the more virulent B. cenocepacia
strain to lung epithelial cells relative to B. multivorans.
Identification of proteins involved in lung cell attachment.
To identify proteins involved in the attachment of Bcc bacteria to
host cells, membrane proteins were prepared from two Bcc spe-
cies, B. multivorans and B. cenocepacia, which represent the most
frequently isolated and the most virulent species, respectively.
Membrane proteins transferred onto PVDF membranes were
probed with either CF or non-CF cells (Fig. 1). Several of the
proteins identified were common to both CFBE41o and
16HBE14o cell-probed blots. Fourteen distinct proteins were
identified across both species (Table 2). There were seven proteins
identified from CFBE41o-probed blots prepared from mem-
brane proteins of the piliated B. cenocepacia strain BC7 (Fig. 3B),
three of which were also identified in 16HBE14o blots (Fig. 3C).
The seven proteins were all in themolecularmass range of 15 to 38
kDa and included some proteins with known roles in the attach-
ment of Bcc bacteria, such as the type VI secretion system (T6SS).
Other identified proteins had not been shown previously to be
involved in host cell attachment of Bcc bacteria, including linocin
andOmpW (Fig. 3B and C and Table 2). In each case, the proteins
were identified with high sequence coverage (	42%) (Table 2).
When blots prepared from the piliated B. cenocepacia strain BC7
were probed with 16HBE14o cells, six proteins were identified,
including a T6SS protein and linocin but not OmpW (Fig. 3C).
The proteins identified on the CFBE41o-probed blots from the
nonpiliated B. cenocepacia strain C1394 showed weaker spot in-
tensities but again included OmpW and linocin (Table 2). The
C1394 blot probedwith 16HBE14o cells showed only two strong
protein spots, corresponding to an Hcp1 family T6SS effector and
an OmpA/MotB domain-containing protein (Table 2).
Membrane proteins from two B. multivorans strains,
LMG13010 and C1962, were also prepared and individually ana-
lyzed. The 2D gel separation of membrane proteins from either
strain showed
150 distinct protein spots, whichwere visible after
Coomassie blue staining, wheremost of the spots were found to be
in the pH 4 to 10.5 range. Four spots were reproducibly identified
between 20 kDa and 30 kDa as being positive for cellular attach-
ment in the B. multivorans strain LMG13010 blot probed with
CFBE41o cells (Fig. 3E and Table 2). Linocin (Fig. 3E, arrow 2)
was identified in two separate regions of the blot and may be
involved in binding to other proteins. Four spots were apparent
on CFBE41o cell-probed blots prepared from B. multivorans
strain C1962, all of which had been observed in other strains:
linocin, OmpW,OmpA/MotB, and theHcp1 family T6SS effector
(Table 2). Two of these four spots were identified on blots probed
with non-CF cells in the region of 20 kDa to 30 kDa: linocin and
OmpA/MotB domain-containing protein. Consistent with B.
FIG 2 Attachment of Bcc to CFBE41o and 16HBE14o cells was examined
by confocal microscopy at MOIs of 10:1 (A) and 50:1 (B). Attached bacteria
were labeled with FITC-labeled antibody, and cells were stained with DAPI.
Each bar represents means ( standard errors of the means) of data from two
independent experiments, with 10 fields counted per strain. Statistical signif-
icance was determined by one-way ANOVA (***, P 0.001; **, P 0.005; *,
P 0.01).
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cenocepacia, OmpW was not identified on 16HBE14o cell-
probed blots of B. multivoransmembrane proteins.
Several proteins that were identified with distinct GenInfo
Identifier (GI) sequence identification numbers shared consider-
able homology and identity with other proteins identified. For
example, two hypothetical proteins (GI 134294574 and GI
78065037) were identified, both of which were 96% homologous
to Hcp1 family type VI secretion family effectors by BLAST anal-
ysis (40). Hcp1was also identified as being involved in the binding
of one strain from each of the two species analyzed, the nonpili-
ated B. cenocepacia strain C1394 and B. multivorans strain C1962.
These proteins were distinct from two other T6SS effector pro-
teins identified (GI 161526099 and GI 493817763). While both of
these T6SS effector proteins shared 97% identity to each other
across the entire sequence, they shared only 6% identity with
Hcp1within theN-terminal region. Twoother closely related pro-
teins were also identified: OmpW (GI 107029064) and OmpW
superfamily protein (GI 161524680). These proteins shared 88%
identity and are grouped together. The latter protein was more
frequently identified, being identified over 15 times across all 4
strains, while OmpW (GI 107029064) was identified in C1394
blots only (n 3) and is consequently not highlighted in Table 2.
Two histone family DNA-binding proteins were also observed
(Table 2). Although not identical, they were homologous at the N
termini, with 95% identity over 100 amino acids at the N termini.
A universal stress family protein was also identified across both
species (GI 493452066). This protein shared 94% homology with
another identified protein, UspA domain-containing protein (GI
501174111). Overall, six of the proteins are membrane proteins.
Although only four proteins were classified as outer membrane
proteins on the PSORTbwebsite (http://www.psort.org/), two ad-
ditional proteins (hypothetical proteins Bmul_4929 and
Bmul_4930) were identified asmembrane proteins in theUniProt
database (41), being classified as a transmembrane protein and a
lipoprotein, respectively.
Investigations of immunogenicity ofmembrane proteins in-
volved in Bcc attachment using CF patient sera. Many proteins
expressed under in vitro culture conditions may not be expressed
during in vivo infection. Therefore, the expression of the antigens
during infection was confirmed by immunoblotting of Bcc mem-
brane proteins with pooled sera from Bcc-colonized CF patients.
All immunoblots probed with Bcc-positive sera showed strong
antibody responses to membrane proteins from all four strains.
The corresponding membrane proteins on parallel Coomassie
blue-stained gels were analyzed byMALDI-TOFMS.Over 50 pro-
teins were identified as being immunogenic (36). Linocin and
OmpWwere identified as being immunoreactive on 2D blots pre-
pared frommembrane fractions of all four strains examinedwhen
serum from Bcc-colonized patients was used (Table 3). Neither
protein was identified in control blots from patients who had no
history of Bcc colonization. This shows that these two proteins are
both expressed by the bacteria during human infection and ex-
posed to, and targeted by, the immune system.
Confirmation of the role of linocin and OmpW in lung cell
attachment. Due to the facts that both linocin and OmpW were
identified in all four strains examined as being involved in attach-
ment to CFBE41o cells, were expressed during human infection,
and were immunogenic, these two proteins were selected for in-
vestigation as protective antigens. Both proteins were cloned and
individually expressed in E. coli BL21 Star cells. Transformation
was confirmed by restriction digestion of extracted plasmid DNA,
and recombinant protein expression was identified in both the
membrane (insoluble) and soluble fractions of whole-cell lysates
for both antigens. In order to confirm that the individual proteins
were involved in host cell attachment, the affinity of the recombi-
nant E. coli clones (E. coli-Lin and E. coli-OmpW) for lung epithe-
lial cells was investigated in order to examine whether the expres-
sion of these proteins enhanced attachment to lung epithelial cells.
As expected, the E. coli BL21 Star strain showed a low level of
attachment to CFBE41o cells, with only 5.02 0.08 cells of the
FIG 3 Representative Coomassie blue-stained 2D gels (A and D) and cell-probed blots (B, C, E, and F) for piliated B. cenocepacia strain BC7 (A to C) and B.
multivorans strain LMG13010 (D to F). Blots in panels B and E were probed with CFBE41o cells, while blots in panels C and F were probed with 16HBE14o
cells. Spots: 1, Hsp20; 2, linocin; 3, mixture of chorismate mutase and linocin; 4, Ahp reductase; 5, type VI secretion system protein; 6, OmpW family protein; 7,
oxidoreductase/aldo-keto reductase; 8, unnamed protein product; 9, unnamed protein product; 10, hypothetical protein Bmul_4390; 11hOmpA/MotB domain
protein. Each gel or blot is representative of data from at least two independent experiments.
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expression strain BL21 Star attaching per 100 CFBE41o cells
within 30 min. When recombinant linocin-expressing E. coli cells
were applied, attachment increased by 4.2-fold (P 0.026), con-
firming the role of linocin in attachment (Fig. 4). The OmpW-
expressing recombinant strain showed a 3.9-fold (P 0.006) in-
crease in attachment to CFBE41o cells over control BL21 cells.
Protection of immunized mice against challenge. Both anti-
gens were purified by using Ni-NTA affinity columns followed by
TABLE 3 Identification of linocin and OmpW from 2D blots probed with sera from Bcc-colonized CF patients compared with control blots using
sera from CF patients with no history of Bcc infection
GI sequence identifier Protein (species) Molecular mass (kDa)/pIa Strain Sequence coverage (%) Scoreb
GI 161524680 OmpW family protein 22.9/9 BC7 27–85 54–142
C1394 10 74–78
LMG10303 29–85 108–253
C1962 36–84 43–222
GI 221198593 Linocin (B. multivorans) 28.8/4.8 BC7 73.8–78.2 155–572
GI 170735569 Linocin (B. cenocepacia)c 28.8/4.8 C1394 41.7–50.9 76–89
GI 221198593 Linocin (B. multivorans) 28.8/4.8 LMG13010 34–81 193–488
GI 221198593 Linocin (B. multivorans) 28.8/4.8 C1962 48.3–90 105–141
a Theoretical molecular masses (kilodaltons) and isoelectric points were determined by Mascot analysis.
b Ranges represent MS/MS ion scores determined by mass fingerprinting. Only scores that were deemed to be significant by Mascot analysis (P 0.05) are reported.
c Query coverage of 96%; 92% identity.
FIG 4 (A to F) Attachment of recombinant E. coli cells expressing either linocin (C and D) or OmpW (E and F) to CFBE41o cells by confocal microscopy
compared with E. coli BL21 controls (A). Bacteria (induced with 1 mM IPTG) were applied to CFBE41o cells (MOI of 50:1) for 30 min and stained with
FITC-conjugated anti-E. coli antibody, and epithelial cells were counterstained with phalloidin and DAPI and superimposed with differential interference
contrast imaging. Bars 20 m. Panels B, D, and F show zoomed images to highlight bacteria interacting with epithelial cells. (G) Bacterial cell counts in 20
randomly selected fields for each strain, expressed as the number of bacteria attached per 100 epithelial cells, from two independent experiments. *, P 0.05 as
determined by one-way ANOVA. (H) Purified recombinant linocin and OmpW on a Coomassie blue-stained SDS-PAGE gel. MW, molecular weight (in
thousands).
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desalting and subsequent purification on endotoxin affinity col-
umns to remove lipopolysaccharide (LPS). The purified proteins
were confirmed to have endotoxin levels of 0.25 EU/ml. The
identity of the recombinant proteins was confirmed by MALDI-
TOF MS/MS analysis of the individual protein bands on SDS-
PAGE gels following purification (Fig. 4E).
It was clear that linocin immunization protected mice from
challenge with B. cenocepacia and B. multivorans (Fig. 5). Immu-
nization with linocin reduced the B. cenocepacia burden to barely
detectable levels (mean value of 3 CFU/ml/lung; P  0.000002)
(Fig. 5A). Although the effect on B. multivorans was not as potent
using this protocol, the CFU in the lung were reduced by 4,000-
fold compared to those in unimmunized controls (P 0.015). Bcc
bacteria are invasive pathogens, and they escape the lung and col-
onize the spleen. Immunization with linocin protected mice from
invasion of B. cenocepacia into the spleen to 0.001% (P 0.0004)
(Fig. 5B). B. multivorans is generally less invasive than B. cenoce-
pacia, and this was confirmed in this study, where the unimmu-
nized controls showed less splenic invasion than theB. cenocepacia
controls. Splenic invasion of B. multivorans was reduced by lino-
cin immunization to 10% of that in unimmunized LMG13010-
challenged mice (P 0.018).
OmpW-immunized mice were also protected against B. ceno-
cepacia, with a reduction in lung bacterial counts of 	4 logs
(60,000-fold reduction in bacterial counts; P  0.022) (Fig. 5C).
Immunization with OmpWprotected against B. multivoranswith
a 1-log reduction in bacterial counts (P 0.013) (the lung bacte-
rial countwas reduced to 8%of that in controls). Although splenic
invasion was reduced, this did not reach statistical significance
following OmpW immunization using the protocols described
above (Fig. 5D).
Antibody responses following immunization. The levels of
antigen-specific antibodies were measured in sera of immunized
mice relative to controls. Pooled sera frommice in the immunized
groups showed high endpoint titers of antigen-specific IgG1,
IgG2a, and IgG2b. The IgG1 and IgG2a titers in response to lino-
cin immunization were 0.79  106 and 1.05  106, respectively.
The ratio of IgG2a to IgG1 antibodies in response to linocin (1.32)
was indicative of a bias toward a Th1 response. IgG responses to
OmpW immunization were comparable to those to linocin. The
IgG2a titers (1.05  106) were comparable to the IgG1 titer
(0.95  106), such that the ratio of IgG2a to IgG1 in response to
OmpW was suggestive of a mixed Th1/Th2 response.
Cellular immune responses. The cytokine responses of anti-
gen-stimulated spleen cells were measured in order to determine
whether one of the antigens resulted in immunological memory
FIG 5 Protection of mice following immunization with linocin (A and B) and OmpW (C and D). Bacterial CFU were counted in lung (A and C) and spleen (B
and D) homogenates from triplicate plates prepared individually from groups of 5 mice. Each study was done two independent times, with comparable results.
Statistical significance was determined by two-way ANOVA (*, P 0.05).
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and to investigate the T-cell response elicited with this antigen.
When previously vaccinated spleen cells were restimulated with
linocin, they produced higher levels of IL-6, IL-17A, and IL-10
than did spleen cells frommice that had not been vaccinated (P
0.05, as determined by Student’s t test) (Fig. 6). OmpW had a
lower ability to stimulate cytokine responses, with only IL-17A
and IL-6 showing statistically significant secretion (P  0.05)
upon reexposure to the antigen. This suggests that the mice im-
munized with either linocin or OmpWdeveloped immunological
memory andwere able to initiate a greater immune response upon
reexposure than that in nonvaccinated mice. IL-17 secretion is
indicative of a typicalmurine Th17 response, while IL-6 and IL-10
are indicative of a Th2 cell response. Although the level of IFN-
secretion was low in response to both antigens, overall, the cyto-
kine profile is suggestive of a mixed Th1/Th17/Th2 response.
Overall, the potential for both antigens is confirmed in these ex-
periments due to the induction of immunological memory and
potent recall cytokine production.
DISCUSSION
This study describes a method to identify potentially potent vac-
cine antigens by identifying bacterial proteins that mediate high-
affinity adherence to host cells. While this method may not iden-
tify all adhesins, it allows the selection of avidly binding adhesins.
The effectiveness of this method was demonstrated by the identi-
fication of two novel potent antigens, linocin and OmpW, which
protected mice against two different species of the cystic fibrosis-
associated pathogens in the Bcc.
Broad identificationmethods such as reverse vaccinology have
been excellent in identifying previously unidentified antigens for a
host of bacterial infections (2). The very high number of identifi-
able antigens can be a limiting factor, as considerable “weeding
out” of the less immunogenic antigens is required. In contrast, our
novel “cell blot”-based method does not aim to identify all ad-
hesins involved in host cell attachment but selects for strongly
binding adhesins, which consequently have a high potential as
potent vaccine antigens. Neither linocin nor OmpW was previ-
ously shown to be involved in the virulence or host cell attachment
of any Burkholderia species, highlighting the potential for the cell
blot method to identify novel adhesins and potential virulence
factors. The role of these antigens as adhesins was confirmed by an
increase in the attachment ofE. coli cells recombinantly expressing
each of these proteins. Furthermore, immunoproteomic analysis
showed that CF patients colonized with Bcc bacteria produce an-
tibodies that specifically recognize these proteins, demonstrating
that these proteins are expressed during human infection and that
they are immunoreactive. Moreover, neither protein was identi-
fied when blots of Bcc membrane proteins were probed with se-
rum from CF patients with no history of Bcc infection.
This is the first study that involves the use of recombinant
subunit antigens to protect mice against Bcc bacteria. Previously,
mice were protected from B. cenocepacia by using enriched OMPs
that were administered intranasally as a nanoemulsion prepara-
tion (25, 26). Both of those studies demonstrated the potential for
OMPs as protective antigens but were carried out with unpurified
FIG6 Cellular response ofmouse spleen cells upon reexposure to linocin orOmpW(50g/ml). Cytokine levels weremeasured in restimulated spleen cells from
either five linocin-vaccinated mice (gray bars), five OmpW-vaccinated mice (black bars), or five sham-vaccinated mice (PBS controls) (clear bars) following
exposure to linocin, OmpW, or PBS, respectively. All mice were cyclophosphamide free. (A) IFN-; (B) IL-4; (C) IL-17A; (D) IL-10; (E) IL-6. *, P 0.05; **, P
0.01; ***, P 0.001 (as determined by Student’s t test).
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OMP preparations, which are ill defined, rather than pure specific
identified antigens. A 17-kDa OMPwas identified as an immuno-
dominant antigen in the latter study (26). Those previous studies
were also carried outwith non-CFmice, as bothBALB/c andCD-1
mice are well-established models for Bcc infection.
Linocin is expressed by the twomost clinically relevant species
of the Bcc, B. multivorans and B. cenocepacia, and has homologs in
at least seven Bcc species, including B. ambifaria, B. pyrrocinia, B.
vietnamiensis, B. dolosa, and B. lata. The gene is also present in
non-Bcc species, including B. gladioli, B. phymatum, B. xeno-
vorans, and Burkholderia sp., but not in any of the sequenced B.
pseudomallei strains. It is well conserved, with identities of 81 to
100% across Bcc species (40), and has been identified as being
involved in attachment to lung epithelial cells in both individual
strains of both Bcc species examined. It is predicted to be an en-
capsulating protein for peroxidase (42). Linocin was previously
described as having antimicrobial activity in Brevibacterium linens
(43) and was subsequently identified as having a role in T-cell
stimulation inMycobacterium tuberculosis but showed no bacteri-
ocin activity (44). It is widely distributed in mycobacterial species
(44). Sutter et al. showed that linocin-like proteins form large
assemblies and are involved in the encapsulation of enzymes (45).
This protein was not shown to be involved in host cell attachment
or in the pathogenesis of Bcc bacteria prior to this study. The dual
roles of linocin in the attachment of Bcc bacteria to lung epithelial
cells and in immunogenicity during human Bcc infection, to-
gether with its previously reported role in eliciting an immune
response in an unrelated respiratory pathogen, suggested that it
would make a potent protective antigen.
OmpW is an outer membrane protein that is also expressed by
both Bcc species examined and is involved in the attachment of
both Bcc species to CFBE41o cells, and its role in attachment was
confirmed by using the recombinant Bcc OmpW-expressing E.
coli strain. BLAST analysis of a Bcc OmpW family protein (GI
161524680) indicated that the most closely related proteins are all
expressed by members of the Bcc. Other strains that express ho-
mologous OmpW proteins include strains of another CF-associ-
ated pathogen, Pandoraea pnomenusa, and another proteobacte-
rium, Sphingomonas (86% identity) (40). Its homolog in P.
aeruginosa is OprG (GI 610414171; 32% identity) (40), which is
involved in host cell toxicity associated with P. aeruginosa (46).
More recently, OprG expression was downregulated from early to
late isolates colonizing adults with CF, which correlated with a
reduction of virulence in the later-colonizing isolates (47).
OmpW proteins have been identified in bacteria that colonize the
gastrointestinal tract, e.g., Vibrio cholerae (48). Its role in the at-
tachment of, and immune response to, a number of intestinal
pathogens was recently reviewed (49). OmpWproteins have been
associated with the attachment of Vibrio alginolyticus; OmpW-
deficient mutants showed a 10-fold reduction in mouse coloniza-
tion (50). OmpW was recently identified as being related to the
immune response in inflammatory bowel disease associated with
an oral pathogen, Porphyromonas gingivalis (51), and is immuno-
genic in Salmonella-induced reactive arthritis (52). We have re-
cently shown that immunization of mice with OmpW also pro-
tects against B. pseudomallei infection (W. T. Casey, N. Spink, F.
Cia, C. Collins, M. Romano, R. Berisio, G. J. Bancroft, and S.
McClean, submitted for publication). Furthermore, it was dem-
onstrated to have protective efficacy as a vaccine antigen against
the fish pathogen Aeromonas hydrophila (53).
OmpW family proteins are found throughout Gram-negative
proteins, which could potentially raise concerns regarding com-
mensal bacteria. The similarity with E. coliOmpW is weak, show-
ing only 36% identity across 88% of the sequence. Other
Gram-positive commensals with OmpW-like domains include
Bacteroides fragilis; however, the homology with Bcc OmpW is
minimal, with only 38% identity over only 3% of the sequence
being observed (40). Furthermore, only four pathogens were
found to share 	37% identity across 90% of the sequence; the
remainder shared30% homology.
Although we did not target proteins that bound specifically to
CF cells, we were interested in comparing the binding of Bcc bac-
teria to epithelial cells of CF and non-CF origins and found that
Bcc bacteria bound at least 2-foldmore to CFBE41o cells than to
14HBE14o cells. Thismay be due, at least in part, to the different
proteins identified on membrane protein blots probed with
CFBE41o cells relative to 16HBE14o cells, and more proteins
were identified on CFBE41o cell blots than on 16HBE14o cell
blots. Indeed, bothOmpWand alkyl hydroperoxide (Ahp) reduc-
tase were absent in all 16HBE14o cell-probed blots. Further
analysis of any specificity in the binding of OmpW or Ahp to cells
with a CF phenotype will need to be addressed by using primary
lung epithelial cells from people with and without CF.
Several other proteins identified as being involved in host cell
attachment in this study were also found to be immunogenic in
our previously reported immunoproteomic analysis (36). These
proteins include Ahp reductase, which was immunogenic across
all 4 of the strains used; Hcp1; OmpA/MotB domain-containing
protein; oxidoreductase/aldo-keto reductase; and acetyl coen-
zyme A (acetyl-CoA) acetyltransferase. This suggests that their
exposure to, and stimulation of, the host humoral system is also a
result of their role in attachment to host epithelial cells and will be
the focus of future work. It is worth highlighting that although we
used a membrane preparation for our blots, we identified eight
proteins that are predicted to be cytosolic proteins.We and others
have reported this previously (36, 54). In particular, Riedel et al.
showed that of the 304 intracellular proteins identified in their full
proteomic analysis of B. cenocepacia, 46 were located in extracel-
lular or surface fractions (54). These proteins that are predicted to
be cytosolic may be expressed in outer membrane vesicles, result-
ing in their consequent inclusion in membrane preparations; for
example, elongation factor Tu is predicted to be cytosolic but has
been shown to be secreted in outer membrane vesicles and was
immunoprotective against B. thailandensis in mice (55).
Our main objective in these studies was to identify potential
vaccine antigens. Both individual antigens tested protected mice
from both B. cenocepacia and B. multivorans challenges following
two immunizations. Protectionwas greatest againstB. cenocepacia
over B. multivorans, and lung CFU were reduced in mice immu-
nized with OmpW and, to a greater extent, linocin. Both antigens
also elicited potent serological responses. Of particular interest
was the finding that both antigens were able to overcome the po-
larizing Th2 effect of the adjuvant alum, inducing mixed Th1/
Th2/Th17 responses, indicating that both antigens in particular
have some adjuvant properties despite the undetectable levels of
endotoxin in these preparations. Linocin proved to be effective as
a stimulant of the cellular host response, with stimulation of IL-
17, IL-6, and IL-10 production from antigen-restimulated spleno-
cytes. Restimulation of spleen cells from OmpW-vaccinated mice
with OmpW also stimulated IL-6, IL-10, and IL-17A comparably
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to the linocin profile albeit at reduced levels. The role of IL-17 in
protection against extracellular bacterial pathogens has been well
described. While the cell-mediated responses required to protect
against Bcc have not been studied to date, the stimulation of IL-
17A by both antigens is likely to contribute to protection against
Bcc infection by these antigens, which have both an extracellular
and an intracellular component to their lifestyle (27, 56–60). IL-
17-stimulating antigens were recently shown to confer protection
against P. aeruginosa in immunization studies (61). Although fur-
ther studies, such as immunization and protection of another an-
imal species, toxicity studies, and clinical trials, on the potential of
these two antigens as vaccine candidates to protect or treat CF
patients and other susceptible populations against Bcc infection
need to be carried out, the current data indicate that the two an-
tigens OmpW and linocin show promise as protective antigens.
Indeed, the recent finding that linocin-like proteins form large
assemblies (45) further highlights the potential of linocin as a vac-
cine antigen.
In summary, the cell blot method identified several proteins
that are involved in attachment to human lung epithelial cells.
Although many of these proteins have no previously known role
in attachment to date, several were recently found to be immuno-
genic in CF patients (36). Furthermore, two of the adhesins were
protective antigens in a mouse challenge study. The method that
we have developed to identify bacterial adhesins that bind avidly
to host cells could be applied to any bacterial pathogen that colo-
nizes mucosal surfaces. By probing 2D membranes with relevant
host epithelial cells, with rigorous wash steps, bacterial adhesins
can be identified by using MALDI-TOF MS analysis. We have
validated this method for the identification of novel adhesins that
were expressed in two Bcc species. This highlights the potential of
our cell blot method to identify novel and potent antigens against
highly multidrug-resistant bacteria.
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